Anthrax - Pipeline Review, H1 2014
2014 Jun 30
152 Pages (PDF)
Anthrax - Pipeline Review, H1 2014 Summary Global Markets Directs, Anthrax - Pipeline Review, H1 2014, provides an overview of the Anthraxs therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Anthrax, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anthrax and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Anthrax - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Anthrax and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Anthrax products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Anthrax pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Anthrax - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Anthrax pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Anthrax Overview 8 Therapeutics Development 9 Pipeline Products for Anthrax - Overview 9 Pipeline Products for Anthrax - Comparative Analysis 10 Anthrax - Therapeutics under Development by Companies 11 Anthrax - Therapeutics under Investigation by Universities/Institutes 15 Anthrax - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Anthrax - Products under Development by Companies 20 Anthrax - Products under Investigation by Universities/Institutes 22 Anthrax - Companies Involved in Therapeutics Development 23 Bristol-Myers Squibb Company 23 Aradigm Corporation 24 Bavarian Nordic A/S 25 Emergent BioSolutions Inc. 26 Grifols, S.A. 27 The Medicines Company 28 Oragenics, Inc. 29 Soligenix, Inc. 30 Elusys Therapeutics, Inc. 31 Green Cross Corporation 32 Summit Corporation plc 33 Evolva SA 34 Protein Potential, LLC 35 ProThera Biologics, LLC. 36 MacroGenics, Inc. 37 Planet Biotechnology Inc. 38 Vaxin, Inc. 39 Microbiotix, Inc. 40 NanoBio Corporation 41 Immunovaccine, Inc. 42 iBio, Inc. 43 Cellceutix Corporation 44 Tetraphase Pharmaceuticals Inc. 45 Hawaii Biotech, Inc. 46 PaxVax 47 Pfenex Inc. 48 SelectX Pharmaceuticals, Inc. 49 Revivicor, Inc. 50 Navigen Pharmaceuticals, Inc. 51 Innovative Biologics, Inc. 52 ContraFect Corporation 53 PsiOxus Therapeutics, Ltd. 54 Conkwest, Inc. 55 Anthrax - Therapeutics Assessment 56 Assessment by Monotherapy Products 56 Assessment by Target 57 Assessment by Mechanism of Action 60 Assessment by Route of Administration 63 Assessment by Molecule Type 65 Drug Profiles 68 ETI-204 - Drug Profile 68 NP-015 - Drug Profile 70 AV-7909 - Drug Profile 71 GC-1109 - Drug Profile 72 PreviThrax - Drug Profile 73 MDX-1303 - Drug Profile 74 AVP-21D9 - Drug Profile 76 Anthrax Vaccine - Drug Profile 77 ARD-1100 - Drug Profile 78 ARD-3100 - Drug Profile 79 MVA-BN Anthrax - Drug Profile 81 MU-1140 - Drug Profile 82 EV-021 - Drug Profile 84 oritavancin disphosphate - Drug Profile 85 CST-102 - Drug Profile 87 PMX-30016 - Drug Profile 88 AdVAV Anthrax Vaccine - Drug Profile 89 SMT-15000 - Drug Profile 91 Subunit Vaccine For Anthrax - Drug Profile 92 Monoclonal Antibody For Respiratory Anthrax - Drug Profile 93 Anthrax Vaccine - Drug Profile 94 Px-563L - Drug Profile 95 TP-271 - Drug Profile 96 PolyMap - Drug Profile 97 anthrax vaccine - Drug Profile 98 Subunit Vaccine for Anthrax - Drug Profile 99 Small Molecules to Inhibit MMP - Drug Profile 100 Human Antibody Based Vaccines - Drug Profile 101 Subunit Vaccine For Anthrax-Plague Combination - Drug Profile 103 SGX-204 - Drug Profile 104 Anthrax Program - Drug Profile 105 GREANX - Drug Profile 106 W1-mAb - Drug Profile 107 Live Attenuated Vaccine for Anthrax - Drug Profile 108 IAIP - Drug Profile 109 PBI-220 - Drug Profile 110 Small Molecules to Inhibit Lethal Factor for Anthrax - Drug Profile 111 Small Molecules for Bacterial Infections - Drug Profile 112 anthrax vaccine next generation - Drug Profile 113 KKL-35 - Drug Profile 114 Small Molecules Inhibiting Anthrax Lethal Factor Toxin for Anthrax - Drug Profile 115 Slit2N - Drug Profile 116 Bifunctional Antibiotics for Anthrax and Cystic Fibrosis - Drug Profile 118 CF-308 - Drug Profile 119 CF-307 - Drug Profile 120 Anthrax - Recent Pipeline Updates 121 Anthrax - Dormant Projects 139 Anthrax - Discontinued Products 140 Anthrax - Product Development Milestones 141 Featured News & Press Releases 141 Appendix 148 Methodology 148 Coverage 148 Secondary Research 148 Primary Research 148 Expert Panel Validation 148 Contact Us 149 Disclaimer 149
Bristol-Myers Squibb Company Aradigm Corporation Bavarian Nordic A/S Emergent BioSolutions Inc. Grifols, S.A. The Medicines Company Oragenics, Inc. Soligenix, Inc. Elusys Therapeutics, Inc. Green Cross Corporation Summit Corporation plc Evolva SA Protein Potential, LLC ProThera Biologics, LLC. MacroGenics, Inc. Planet Biotechnology Inc. Vaxin, Inc. Microbiotix, Inc. NanoBio Corporation Immunovaccine, Inc. iBio, Inc. Cellceutix Corporation Tetraphase Pharmaceuticals Inc. Hawaii Biotech, Inc. PaxVax Pfenex Inc. SelectX Pharmaceuticals, Inc. Revivicor, Inc. Navigen Pharmaceuticals, Inc. Innovative Biologics, Inc. ContraFect Corporation PsiOxus Therapeutics, Ltd. Conkwest, Inc.